UBS’s Emergent Biosolutions EBS Stock Holding History

UBS’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,564	Closed	-$39K	–	10498
2014 Q1	$39K	Buy	+1,564	New	+$39.5K	﹤0.01%	7169
2013 Q4	–	Sell	-2,064	Closed	-$39K	–	10475
2013 Q3	$39K	Buy	+2,064	New	+$36.8K	﹤0.01%	7167

Other funds holding EBS

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS's EBS Position: Q2 2014 in Review

UBS sold out of Emergent Biosolutions (EBS) in Q2 2014, closing a stake of 1,564 shares — an estimated $39K sold.

UBS first reported a position in EBS in Q3 2013 and held it in 2 quarters. The position peaked at $39K in Q1 2014. 160 funds tracked by Wall St. Rank hold EBS as of Q2 2014.

UBS reported no remaining Emergent Biosolutions position as of Q2 2014 after selling out during the quarter.
UBS sold 1,564 Emergent Biosolutions shares in Q2 2014, an estimated $39K.
UBS first reported a position in Emergent Biosolutions in Q3 2013 and held it in 2 quarters.
UBS's Emergent Biosolutions position peaked at $39K in Q1 2014.
160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.